ArticleBMC gastroenterology2026
Diagnostic value of CT enterography combined with inflammatory indicators in active Crohn's disease.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveCurrent diagnostic paradigms for Crohn’s disease (CD) activity assessment remain fragmented across imaging and laboratory modalities. This study seeks to investigate the diagnostic efficacy of intestinal computed tomography imaging combined with serum inflammatory markers in detecting active Crohn’s disease (CD).
methodsData from 68 patients undergoing CT enterography (CTE) of the small intestine (43 patients with active CD and 25 controls) were analyzed. CTE findings, including plain CT values and enhanced ΔCT values, as well as neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and platelet-to-albumin ratio (PAR), were collected. The correlations between these indicators and CD activity were also explored. Logistic regression and receiver operating characteristic curve (ROC) analyses were conducted to evaluate the diagnostic value of individual and combined markers for active CD.
resultsSignificant differences in CTE imaging features and serum optimization indices were observed between cases with mild to moderate active CD and controls (P < 0.05). The area under the curve of CTE imaging (venous phase ΔCT value (0.896)) and serum indices (NLR (0.902)) in predicting CD were the highest in the moderately active stage. The area under the curve of the combination of the indices (intestinal wall thickness, enhanced ΔCT value, NLR, PLR, and CAR) was 0.947. Among them, NLR, PLR, and CAR exhibited the highest sensitivity (95.0%), whereas enhanced arterial phase ΔCT value demonstrated a higher specificity (93.8%). Venous-phase ΔCT values and NLR were identified as significant predictors of moderately active CD. Additionally, serum optimization indices were strongly correlated with CTE images (P < 0.01).
conclusionCTE imaging features and serological optimization indicators can serve as potential noninvasive markers for diagnosing active CD, and higher diagnostic value can be achieved through combined assessments. Venous-phase ΔCT values and the NLR are promising markers of moderately active CD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.